Over the course of the forecast period, market expansion is anticipated to be driven by rising research and development initiatives by key players in the market for expanding the worldwide pneumococcal vaccines market. For instance, in June 2020, UNICEF and Serum Institute of India (SII), an Indian biopharmaceutical company, signed a new supply agreement to provide pneumococcal conjugate vaccine (PCV) in low-income nations like Pakistan, Nigeria, Uganda, and Kenya for US$ 2.00 per dose, a 43% discount from the Gavi price at the beginning of the Advance Market Commitment.
Global Pneumococcal Vaccines Market size was valued at US$ 6,615.94 Million in 2022 and is expected to witness a CAGR of 4.4% over the forecast period (2022 – 2030).
Top Companies in the Pneumococcal Vaccines Industry:
1. Pfizer Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. In December, 2022 announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age.